Student Research Committee, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Department of Clinical Research, ScientificWriting Corp, Houston, TX, USA.
Obes Surg. 2023 Dec;33(12):3797-3805. doi: 10.1007/s11695-023-06883-x. Epub 2023 Oct 20.
There are some concerns about the higher risk of certain gastrointestinal (GI) cancers in patients with a history of bariatric metabolic surgery (BMS). The current study aimed to investigate the association of BMS with GI cancer hospital admission including esophageal, gastric, colorectal, small intestinal, liver, gallbladder, bile duct, and pancreatic cancers.
The analysis utilized the US national inpatient sample (NIS) data from 2016 to 2020, employing ICD-10 codes. A propensity score matching in a 3:1 ratio was done to match the BMS and non-BMS groups.
A total of 328,369 patients with a history of BMS and 4,989,154 with obesity and without a history of BMS were included in this study. BMS was independently associated with a higher risk of gastric and pancreatic cancers hospital admission (OR: 1.69 (CI 95%: 1.42-2.01) and OR: 1.46 (CI 95%: 1.27-1.68)), respectively. In addition, BMS was independently associated with a lower risk of colorectal and liver cancer hospital admission (OR: 0.57 (CI 95%: 0.52-0.62) and OR: 0.72 (CI 95%: 0.52-0.98)), respectively. Besides, esophageal, gallbladder, bile duct, and small intestinal cancer were not significantly different between the two groups. In patients with GI cancer, although the BMS group had significantly lower total charges and length of hospital stay compared to the non-BMS group, the rate of in-hospital mortality was not significantly different.
The current study showed that bariatric surgery may be associated with a higher risk of gastric and pancreatic cancer and a lower risk of colorectal and liver cancer hospital admission. Further research is needed to explore this association.
有一些担忧认为,在接受过减重代谢手术(BMS)的患者中,某些胃肠道(GI)癌症的风险更高。本研究旨在调查 BMS 与包括食管、胃、结直肠、小肠、肝、胆囊、胆管和胰腺在内的 GI 癌症住院的相关性。
该分析使用了 2016 年至 2020 年的美国国家住院患者样本(NIS)数据,并采用了 ICD-10 编码。采用倾向评分匹配以 3:1 的比例对 BMS 和非 BMS 组进行匹配。
共有 328369 名有 BMS 病史的患者和 4989154 名肥胖但无 BMS 病史的患者纳入本研究。BMS 与胃癌和胰腺癌住院的风险增加独立相关(OR:1.69(95%CI:1.42-2.01)和 OR:1.46(95%CI:1.27-1.68))。此外,BMS 与结直肠癌和肝癌住院的风险降低独立相关(OR:0.57(95%CI:0.52-0.62)和 OR:0.72(95%CI:0.52-0.98))。此外,食管、胆囊、胆管和小肠癌在两组之间无显著差异。在患有 GI 癌症的患者中,尽管 BMS 组的总费用和住院时间明显低于非 BMS 组,但住院死亡率无显著差异。
本研究表明,减重手术可能与胃癌和胰腺癌的风险增加以及结直肠癌和肝癌的风险降低相关。需要进一步研究来探讨这种相关性。